Vanguard Group’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Vanguard Group’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,865,281	Closed	-$37.2M	–	4617
2022 Q3	$37.2M	Buy	1,865,281 +220,012	+13%	+$2.9M	﹤0.01%	2323
2022 Q2	$11.3M	Sell	1,645,269 -613,487	-27%	-$4.31M	﹤0.01%	2926
2022 Q1	$21M	Sell	2,258,756 -601,897	-21%	-$6.41M	﹤0.01%	2749
2021 Q4	$40.7M	Buy	2,860,653 +67,755	+2%	+$1.17M	﹤0.01%	2471
2021 Q3	$64.8M	Buy	2,792,898 +497,048	+22%	+$11.8M	﹤0.01%	2223
2021 Q2	$57.1M	Buy	2,295,850 +102,994	+5%	+$2.77M	﹤0.01%	2299
2021 Q1	$61.4M	Buy	2,192,856 +668,281	+44%	+$24.1M	﹤0.01%	2202
2020 Q4	$53.2M	Buy	1,524,575 +567,182	+59%	+$24.7M	﹤0.01%	2169
2020 Q3	$47.7M	Buy	957,393 +877,617	+1,100%	+$35.5M	﹤0.01%	2037
2020 Q2	$3.71M	Buy	+79,776	New	+$3.46M	﹤0.01%	3231

Vanguard Group's FMTX Position: Q4 2022 in Review

Vanguard Group sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 1,865,281 shares — an estimated $37.2M sold.

Vanguard Group first reported a position in FMTX in Q2 2020 and held it in 10 quarters. The position peaked at $64.8M in Q3 2021. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Vanguard Group reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Vanguard Group sold 1,865,281 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $37.2M.
Vanguard Group first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Vanguard Group's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $64.8M in Q3 2021.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.